Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma"

Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932.

Authors

Affiliations

¹ Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland [email protected].
² Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
³ Department of Oncology, University Hospital of Lausanne, Switzerland.
⁴ Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.

No abstract available

Publication types

Comment

MeSH terms

Histiocytic Sarcoma
Humans
Imatinib Mesylate*
Protein-Tyrosine Kinases*
Pyridones
Pyrimidinones

Substances

Pyridones
Pyrimidinones
trametinib
Imatinib Mesylate
Protein-Tyrosine Kinases